Latest News and Press Releases

Reports fourth quarter 2023 total revenue of $6.3 million, representing 45% growth compared to fourth quarter 2022 Reports 2023 revenue of $22.5 million, representing 31% growth compared to 2022 ...

LOWELL, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation...

LOWELL, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation...

The new Rapid Sterility application includes a novel, proprietary test kit that has been developed for use with the Company’s fully automated Growth Direct system and delivers time to organism...

Full year 2023 total revenue expected to be between $22.4 million and $22.6 million, representing growth of over 30% compared to the prior year Fourth quarter 2023 total revenue expected to be...

โลเวลล์ แมสซาชูเซตส์ , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“บริษัท”)...

マサチューセッツ州ローウェル発, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ヘルスケア製品の効率的な製造と迅速かつ安全なリリースを促進するミッションクリティカルな自動化ソリューションを提供する革新的なライフサイエンステクノロジー企業であるラピッド・マイクロ・バイオシステムズ (Rapid Micro Biosystems, Inc.) (NASDAQ: RPID)...

LOWELL, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Perusahaan”), perusahaan teknologi ilmu hayati inovatif yang menyediakan solusi otomatisasi yang...

羅威爾，麻薩諸塞州, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID)（以下簡稱「公司」）是一間創新生命科學技術公司，提供關鍵任務自動化解決方案，以促進醫療保健產品的高效生產和快速、安全發布。該公司今日宣布 Samsung Biologics (KRX: 207940.KS) 選擇了...

洛厄尔，马萨诸塞州, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID)（简称“公司”），一家提供任务关键自动化解决方案以加快医疗保健产品高效生产和快速、安全发布的创新生命科学技术公司，今天宣布 Samsung Biologics (KRX: 207940.KS) 已选择 Growth...